ably high MIC patterns of BLNAR strains in response to beta-lactam antibiotics (beta-lactams) and meropenem arise from the test method or their actual status. To confirm the high MIC values, we compared results of the Etest with those of broth microdilution using H. influenzae isolates with known mechanisms of beta-lactam resistance.
We examined MICs of 153 H. influenzae strains by using the Etest and the broth microdilution method simultaneously ( Table 1) . MICs of all strains were determined by broth microdilution using the standard method (1) and by the Etest according to the manufacturer's instructions. Two persons independently took readings of MICs, and the agreement was almost Ϯlog 2 1. H. influenzae ATCC 49247 was included in each batch as a control. MICs of the Etest were rounded up to the next log 2 concentration, and agreement was defined as the results of broth microdilution and those of Etest in the range of Ϯlog 2 1 of each other. The mutation status of the ftsI gene in all strains was checked by using primers described previously (3, 8) . MICs of BLNAS and beta-lactamase-positive ampicillinresistant (BLPAR) strains showed consistent results by both tests, and the agreement was 92.59 to 100% for beta-lactams and 90 to 92.59% for meropenem, respectively. However, BL-NAR and BLPACR strains showed diverse results, and the agreement for beta-lactam and meropenem decreased to a range of 48.27% to 100% and 42.10% to 44.82%, respectively (Table 1) . Furthermore, 9.2% of the intermediate BLNAR strains determined by the broth microdilution method were highly resistant to ampicillin (256 g/ml) by the Etest method. Similarly, all strains were susceptible to ceftriaxone by broth microdilution, but 42.5 to 68.42% of BLNAR and BLPACR strains showed high MICs to ceftriaxone (32 g/ml). The fluoroquinolone levofloxacin showed high agreement (98.85% to 100%) between microbroth and Etest results (Table 1) .
From these results, we considered that determining MICs to beta-lactams by the Etest is not a reliable method for strains with the fstI mutant gene but is acceptable for BLNAS and BLPAR strains. High MICs to beta-lactams and meropenem may be due to the presence of small colonies within the inhibition ellipses of the Etest and the variable expression of ftsI during bacterial growth between agar and broth media. Matic et al. reported low MICs for BLPACR strains to amoxicillinclavulanate and excluded the possibilities of extended-spectrum beta-lactamase associated with amoxicillin-clavulanate resistance in BLPACR strains (6) . We considered that remarkably high MICs of BLNAR strains might arise from an antibiotic susceptibility method such as the Etest rather than an actual elevation of MICs.
In conclusion, we considered that Etest results alone might not represent the actual MIC status of BLNAR and BLPACR strains for beta-lactams and meropenem. Considering the essential roles of beta-lactams in the treatment of invasive diseases, utilizing only the Etest may misguide a community about the susceptibility of H. influenzae and would enhance the development of BLNAR strains by selection of an inappropriate antibiotic. Although the Etest is not a national or international reference method, it is a convenient commercial product for generating MICs and can be applicable in regions with a low prevalence of BLNAR strains. Finally, we suggest that MICs of H. influenzae isolates should be measured by the broth microdilution method in conjunction with the PCR technique.
